(IART) Integra LifeSciences - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.175m USD | Total Return: 15.8% in 12m
Avg Turnover: 14.7M
EPS Trend: -94.3%
Qual. Beats: 1
Rev. Trend: 93.7%
Qual. Beats: 1
Warnings
Interest Coverage Ratio -4.5 is critical
Altman Z'' 0.80 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
Integra LifeSciences Holdings Corporation (IART) is a medical technology company specializing in neurosurgery, neurocritical care, and regenerative tissue technologies. The company operates through two primary segments: Codman Specialty Surgical and Tissue Technologies. Its product portfolio includes intracranial monitoring equipment, dural repair products, and specialized surgical instruments, as well as biological solutions for chronic wound management and peripheral nerve repair.
The company utilizes a direct sales force and international distribution channels to supply hospitals and surgical centers globally. As a player in the Health Care Equipment sector, Integra operates within a high-barrier-to-entry market characterized by rigorous regulatory oversight and significant research and development requirements. Its business model relies heavily on a mix of capital equipment sales and high-margin recurring revenue from disposable surgical supplies.
Investors can evaluate the company’s long-term growth metrics and valuation trends by visiting ValueRay. Integra LifeSciences is headquartered in Princeton, New Jersey, and has maintained its current corporate structure since 1995.
- Codman Specialty Surgical segment performance dictates core revenue growth and investor sentiment
- Manufacturing quality issues and FDA warning letters pose significant regulatory and supply risks
- Tissue Technologies portfolio expansion drives high-margin growth in wound care and surgical repair
- Strategic acquisitions and product pipeline integration determine long-term market share and valuation
| Net Income: -495.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 2.34 > 1.0 |
| NWC/Revenue: 50.18% < 20% (prev 3.24%; Δ 46.93% < -1%) |
| CFO/TA 0.02 > 3% & CFO 71.4m > Net Income -495.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.0m) vs 12m ago 0.64% < -2% |
| Gross Margin: 53.21% > 18% (prev 0.54%; Δ 5.27k% > 0.5%) |
| Asset Turnover: 72.30% > 50% (prev 167.3%; Δ -94.95% > 0%) |
| Interest Coverage Ratio: -4.52 > 6 (EBITDA TTM -273.7m / Interest Expense TTM 94.3m) |
| A: 0.23 (Total Current Assets 1.17b - Total Current Liabilities 346.8m) / Total Assets 3.58b |
| B: 0.12 (Retained Earnings 418.8m / Total Assets 3.58b) |
| C: -0.19 (EBIT TTM -425.9m / Avg Total Assets 2.27b) |
| D: 0.15 (Book Value of Equity 388.8m / Total Liabilities 2.54b) |
| Altman-Z'' = 0.80 = B |
| DSRI: 1.03 (Receivables 264.4m/252.4m, Revenue 1.64b/1.62b) |
| GMI: 1.01 (GM 53.21% / 53.54%) |
| AQI: -0.88 (AQ_t 0.51 / AQ_t-1 -0.58) |
| SGI: 1.01 (Revenue 1.64b / 1.62b) |
| TATA: -0.16 (NI -495.8m - CFO 71.4m) / TA 3.58b) |
| Beneish M = -4.26 (Cap -4..+1) = AAA |
As of May 27, 2026, the stock is trading at USD 15.19 with a total of 824,187 shares traded.
Over the past week, the price has changed by +7.65%,
over one month by +42.10%,
over three months by +34.07% and
over the past year by +15.78%.
Integra LifeSciences has received a consensus analysts rating of 2.92. Therefore, it is recommended to hold IART.
- StrongBuy: 2
- Buy: 1
- Hold: 5
- Sell: 2
- StrongSell: 2
| Analysts Target Price | 16.7 | 10% |
P/E Forward = 6.4558
P/S = 0.7143
P/B = 1.1273
P/EG = 0.6691
Revenue TTM = 1.64b USD
EBIT TTM = -425.9m USD
EBITDA TTM = -273.7m USD
Long Term Debt = 1.83b USD (from longTermDebt, last quarter)
Short Term Debt = 52.7m USD (from shortTermDebt, last quarter)
Debt = 2.21b USD (from shortLongTermDebtTotal, last quarter) + Leases 174.0m
Net Debt = 1.95b USD (calculated: Debt 2.21b - CCE 265.5m)
Enterprise Value = 3.12b USD (1.17b + Debt 2.21b - CCE 265.5m)
Interest Coverage Ratio = -4.52 (Ebit TTM -425.9m / Interest Expense TTM 94.3m)
EV/FCF = -308.5x (Enterprise Value 3.12b / FCF TTM -10.1m)
FCF Yield = -0.32% (FCF TTM -10.1m / Enterprise Value 3.12b)
FCF Margin = -0.62% (FCF TTM -10.1m / Revenue TTM 1.64b)
Net Margin = -30.15% (Net Income TTM -495.8m / Revenue TTM 1.64b)
Gross Margin = 53.21% ((Revenue TTM 1.64b - Cost of Revenue TTM 769.5m) / Revenue TTM)
Gross Margin QoQ = 57.22% (prev 49.52%)
Tobins Q-Ratio = 0.87 (Enterprise Value 3.12b / Total Assets 3.58b)
Interest Expense / Debt = 4.26% (Interest Expense 94.3m / Debt 2.21b)
Taxrate = 21.0% (US default 21%)
NOPAT = -336.5m (EBIT -425.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.38 (Total Current Assets 1.17b / Total Current Liabilities 346.8m)
Debt / Equity = 2.12 (Debt 2.21b / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = -7.12 (negative EBITDA) (Net Debt 1.95b / EBITDA -273.7m)
Debt / FCF = -192.5 (out of range, set to none) (Net Debt 1.95b / FCF TTM -10.1m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = -21.80% (Net Income -495.8m / Total Assets 3.58b)
RoE = -47.65% (Net Income TTM -495.8m / Total Stockholder Equity 1.04b)
RoCE = -14.86% (EBIT -425.9m / Capital Employed (Equity 1.04b + L.T.Debt 1.83b))
RoIC = -10.25% (negative operating profit) (NOPAT -336.5m / Invested Capital 3.28b)
WACC = 6.46% (E(1.17b)/V(3.39b) * Re(12.29%) + D(2.21b)/V(3.39b) * Rd(4.26%) * (1-Tc(0.21)))
Discount Rate = 12.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -34.10 | Cagr: -0.78%
[DCF] Fair Price = unknown (Cash Flow -10.1m)
EPS Correlation: -94.33 | EPS CAGR: -13.36% | SUE: 2.82 | # QB: 1
Revenue Correlation: 93.69 | Revenue CAGR: 2.96% | SUE: 1.10 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.48 | Chg30d=-7.65% | Revisions=-40% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.56 | Chg30d=-4.06% | Revisions=-27% | Analysts=9
EPS current Year (2026-12-31): EPS=2.45 | Chg30d=+4.62% | Revisions=+64% | GrowthEPS=+9.8% | GrowthRev=+2.5%
EPS next Year (2027-12-31): EPS=2.61 | Chg30d=+1.87% | Revisions=+45% | GrowthEPS=+6.6% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: +64%